REG - Redx Pharma plc - Result of AGM

Redx PharmaAnnouncement

14/03/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240314:nRSN8915Ga&default-theme=true

RNS Number : 8915G  Redx Pharma plc  14 March 2024

REDX PHARMA PLC

 

("Redx" or the "Company")

 

Result of Annual General Meeting

 

Alderley Park, UK, 14 March 2024 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that its Annual General Meeting was held at 11am on 14
March 2024, with all resolutions passed by substantial majorities.

 

The table below sets out the details of the votes put to shareholders:

 

 Resolution number  Resolution name                           Number of votes for & discretionary      % of votes for & discretionary      Number of votes against  % of votes against  % of votes withheld*  Total votes cast (including withheld)
 1                  Receive the Company's annual accounts     351,887,218                              94.48%                              20,551,504               5.52%               0.00%                 372,438,722
 2                  Re-appoint Ernst & Young as auditors      372,434,833                              100.00%                             2,586                    0.00%               0.00%                 372,438,722
 3                  Elect Dr Joseph Anderson as a director    372,408,267                              99.99%                              3,889                    0.00%               0.01%                 372,438,722
 4                  Re-elect Dr Jane Griffiths as a director  372,407,145                              99.99%                              5,011                    0.00%               0.01%                 372,438,722
 5                  Re-elect Peter Presland as a director     351,851,226                              94.47%                              20,558,505               5.52%               0.01%                 372,438,722
 6                  Re-elect Dr Robert Scott as a director    351,854,954                              94.47%                              20,557,202               5.52%               0.01%                 372,438,722
 7                  Authorise the directors to allot shares   372,396,854                              99.99%                              41,868                   0.01%               0.00%                 372,438,722
 8                  Disapply pre-emption rights               372,266,621                              99.96%                              164,843                  0.04%               0.00%                 372,438,722

*A vote withheld is not a vote in law and is not counted in the calculation of
the proportion of votes 'For' or 'Against'

 

 

 For further information, please contact:

 Redx Pharma Plc                                                                            T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)
 SPARK Advisory Partners (Nominated Adviser)                                                T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                                             T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                                                 T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                                             T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor, zelasudil (RXC007), is in development for
interstitial lung disease and is undergoing a Phase 2a trial for idiopathic
pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is in Phase 1 development with
healthy volunteer data expected by the end of 2024. Redx's lead oncology
product candidate, the Porcupine inhibitor zamaporvint (RXC004), being
developed as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data during the first half of
2024, following which Redx will seek a partner for ongoing development.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the
only non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPUAUWUPCGGC